Nehal J. Lakhani

机构：Van Andel Institute, South Texas Accelerated Research Therapeutics, Center for Cancer Research, Start Treatment & Recovery Centers · ORCID：0009-0005-6327-0176

发表论文 310 篇 · 总被引 4752 次 · h-index 28

代表论文

• Initial results from NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma. (2026 · Journal of Clinical Oncology · 被引 2)
• Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer (2026 · British Journal of Cancer · 被引 2)
• Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies (2026 · Cancer · 被引 1)
• Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers (2026)
• Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers (2026)
• Supplementary Table S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers (2026)